

- Limon J, Turc-Carel C, Dal Cin P, et al. Recurrent chromosome translocations in liposarcoma. *Cancer Genet Cytogenet* 1986;22:93–94.
- Crozat A, Aman P, Mandahl N, et al. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. *Nature* 1993;363:640–644.
- Powers MP, Wang WL, Hernandez VS, et al. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. *Mod Pathol* 2010;23:1307–1315.
- Willems SM, Schrage YM, Bruijn IH, et al. Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option. *Mol Cancer* 2010;9:257.
- Charytonowicz E, Terry M, Coakley K, et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. *J Clin Invest* 2012;122:886–898.
- Schwarzbach MH, Koesters R, Germann A, et al. Comparable transforming capacities and differential gene expression patterns of variant FUS/CHOP fusion transcripts derived from soft tissue liposarcomas. *Oncogene* 2004;23:6798–6805.
- Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. *Genes Dev* 1994;8:2513–2526.
- Barone MV, Crozat A, Tabaei A, et al. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. *Genes Dev* 1994;8:453–464.
- Kuroda M, Ishida T, Takanashi M, et al. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. *Am J Pathol* 1997;151:735–744.
- Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. *Nat Cell Biol* 2011;13:184–190.
- Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. *Mol Cancer Ther* 2009;8:449–457.
- Goeransson M, Andersson MK, Forni C, et al. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ. *Oncogene* 2009;28:270–278.
- Cheng H, Dodge J, Mehl E, et al. Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. *Hum Pathol* 2009;40:1244–1251.
- Lanckohr C, Kasprzyński A, Klein-Hitpass L, et al. [Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation]. *Pathologie* 2010;31:60–66.
- Tajima T, Morii T, Kikuchi F, et al. Significance of LRP and PPAR-gamma expression in lipomatous soft tissue tumors. *Open Orthop J* 2010;4:48–55.
- Borjigin N, Ohno S, Wu W, et al. TLS-CHOP represses miR-486 expression, inducing upregulation of a metastasis regulator PAI-1 in human myxoid liposarcoma. *Biochem Biophys Res Commun* 2012;427:355–360.
- Oikawa K, Tanaka M, Itoh S, et al. A novel oncogenic pathway by TLS-CHOP involving repression of MDA-7/IL-24 expression. *Br J Cancer* 2012;106:1976–1979.
- Willmore-Payne C, Holden J, Turner KC, et al. Translocations and amplifications of chromosome 12 in liposarcoma demonstrated by the LSI CHOP breakpoint rearrangement probe. *Arch Pathol Lab Med* 2008;132:952–957.
- Fiore M, Grosso F, Lo Vullo S, et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 2007;109:2522–2531.
- Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. *Clin Cancer Res* 2001;7:3977–3987.
- Hoffman A, Ghadimi MP, Demicco EG, et al. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. *Cancer* 2013;119:1868–1877.
- Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy. *Nat Genet* 2010;42:715–721.
- Mentzel T, Brown LF, Dvorak HF, et al. The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma. *Virchows Arch* 2001;438:13–22.
- de Vreeze RS, de Jong D, Haas RL, et al. Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern. *Int J Radiat Oncol Biol Phys* 2008;72:1480–1487.
- Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012;23:771–776.
- Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. *J Clin Pathol* 2003;56:96–102.
- Ordóñez JL, Osuna D, Herrero D, et al. Advances in Ewing's sarcoma research: where are we now and what lies ahead? *Cancer Res* 2009;69:7140–7150.
- Sankar S, Lessnick SL. Promiscuous partnerships in Ewing's sarcoma. *Cancer Genet* 2011;204:351–365.
- Paronetto MP. Ewing sarcoma protein: a key player in human cancer. *Int J Cell Biol* 2013;2013:642853.
- Abaan OD, Levenson A, Khan O, et al. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's sarcoma tumorigenesis. *Oncogene* 2005;24:2715–2722.
- Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-beta abolishes Ewing sarcoma growth. *Cancer Res* 2012;72:4494–4503.
- Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells. *Oncogene* 2008;27:6034–6043.
- Niedan S, Kauer M, Aryee DN, et al. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. *Oncogene* 2013 Sep 2 [Epub ahead of print].
- Sankar S, Bell R, Stephens B, et al. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma. *Oncogene* 2013;32:5089–5100.
- Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol* 2004;24:7275–7283.
- De Vito C, Riggi N, Suva ML, et al. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development. *PLoS One* 2011;6:e23592.
- Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. *PLoS One* 2008;3:e1965.
- Stoll G, Surdez D, Tirode F, et al. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis. *Nucleic Acids Res* 2013;41:8853–8871.
- Bilke S, Schwentner R, Yang F, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. *Genome Res* 2013;23:1797–1809.
- Kovar H. Downstream EWS/FLI1 - upstream Ewing's sarcoma. *Genome Med* 2010;2:8.
- Yamaguchi U, Hasegawa T, Morimoto Y, et al. A practical approach to the clinical diagnosis of Ewing's sarcoma/primitive neuroectodermal tumour and other small round cell tumours sharing EWS rearrangement using new fluorescence in situ hybridisation probes for EWSR1 on formalin fixed, paraffin wax embedded tissue. *J Clin Pathol* 2005;58:1051–1056.
- Warren M, Weindel M, Ringrose J, et al. Integrated multimodal genetic testing of Ewing sarcoma—a single-institution experience. *Hum Pathol* 2013;44:2010–2019.
- Kelleher FC, Thomas DM. Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours. *Clin Sarcoma Res* 2012;2:6.
- Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. *Pharmacol Ther* 2013;137:216–224.
- Erkizan HV, Kong Y, Merchant M, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. *Nat Med* 2009;15:750–756.
- Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. *Semin Cancer Biol* 2005;15:197–205.
- Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. *Cancer Res* 1994;54:2837–2840.
- Hartwig S, Ho J, Pandey P, et al. Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. *Development* 2010;137:1189–1203.
- Dufresne A, Cassier P, Couraud L, et al. Desmoplastic small round cell tumor: current management and recent findings. *Sarcoma* 2012;2012:714986.
- Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-I insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol* 2012;30:1849–1856.
- Lee SB, Kolquist KA, Nichols K, et al. The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. *Nat Genet* 1997;17:309–313.
- Italiano A, Kind M, Cioffi A, et al. Clinical activity of sunitinib in patients with advanced desmoplastic round cell tumor: a case series. *Target Oncol* 2013;8:211–213.
- Wong JC, Lee SB, Bell MD, et al. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. *Oncogene* 2002;21:2009–2019.
- Subbiah V, Brown RE, Jiang Y, et al. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor (WT1). *PLoS One* 2013;8:e68985.
- Haldar M, Randall RL, Capecci MR. Synovial sarcoma: from genetics to genetic-based animal modeling. *Clin Orthop Relat Res* 2008;466:2156–2167.
- dos Santos NR, Torensmar R, de Vries TJ, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. *Cancer Res* 2000;60:1654–1662.
- Middeljans E, Wan X, Jansen PW, et al. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. *PLoS One* 2012;7:e33834.

58. Soulez M, Saurin AJ, Freemont PS, et al. SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex. *Oncogene* 1999;18:2739–2746.
59. Cironi L, Provero P, Riggi N, et al. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. *PLoS one* 2009;4:e7904.
60. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. *Cancer Res* 2009;69:3657–3664.
61. Jagdis A, Rubin BP, Tubbs RR, et al. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma. *Am J Surg Pathol* 2009;33:1743–1751.
62. Su L, Sampaio AV, Jones KB, et al. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. *Cancer Cell* 2012;21:333–347.
63. Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. *Cell* 2013;153:71–85.
64. Wilson BC, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. *Cancer Cell* 2010;18:316–328.
65. Naka N, Takenaka S, Araki N, et al. Synovial sarcoma is a stem cell malignancy. *Stem Cells* 2010;28:1119–1131.
66. Barham W, Frump AL, Sherrill TP, et al. Targeting the wnt pathway in synovial sarcoma models. *Cancer Discov* 2013;3:1286–1301.
67. Lee KW, Lee NK, Ham S, et al. Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma. *Cancer Lett* 2014;343:62–73.
68. Garcia CB, Shaffer CM, Alfaro MP, et al. Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2. *Oncogene* 2012;31:2323–2334.
69. Jones KB, Su L, Jin H, et al. SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. *Oncogene* 2013;32:2365–2371.
70. Setsu N, Kohashi K, Fushimi F, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. *Cancer* 2013;119:3504–3513.
71. de Bruijn DR, Allander SV, van Dijk AH, et al. The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. *Cancer Res* 2006;66:9474–9482.
72. Sun Y, Gao D, Liu Y, et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. *Oncogene* 2006;25:1042–1052.
73. Lagarde P, Przybyl J, Brulard C, et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. *J Clin Oncol* 2013;31:608–615.
74. Davis RJ, D'Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. *Cancer Res* 1994;54:2869–2872.
75. Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. *Nat Genet* 1993;5:230–235.
76. Williamson D, Missiaglia E, de Reynies A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. *J Clin Oncol* 2010;28:2151–2158.
77. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. *J Clin Oncol* 2002;20:2672–2679.
78. Wexler LH, Ladanyi M. Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. *J Clin Oncol* 2010;28:2126–2128.
79. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma—genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. *Am J Pathol* 2009;174:550–564.
80. Marshall AD, Grosveld GC. Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. *Skelet Muscle* 2012;2:25.
81. Yuan H, Qin F, Movassagh M, et al. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process. *Cancer Discov* 2013;3:1394–1403.
82. Thuault S, Hayashi S, Lagirand-Cantaloube J, et al. P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. *Oncogene* 2013;32:1876–1887.
83. Ahn EH, Mercado GE, Lae M, et al. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. *Oncol Rep* 2013;30:968–978.
84. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. *Oncogene* 2008;27:6550–6560.
85. Aslam MI, Hettmer S, Abraham J, et al. Dynamic and nuclear expression of PDGFRalpha and IGF-1R in alveolar rhabdomyosarcoma. *Mol Cancer Res* 2013;11:1303–1313.
86. van Gaal JC, Roeffen MH, Flucke UE, et al. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. *Eur J Cancer* 2013;49:3462–3470.
87. Olanich ME, Barr FG. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. *Expert Opin Ther Targets* 2013;17:607–623.
88. Nishijo K, Chen QR, Zhang L, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. *Cancer Res* 2009;69:2902–2911.
89. Mitton B, Federman N. Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. *Sarcoma* 2012;2012:428789.
90. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. *Oncogene* 2001;20:48–57.
91. Kuroda N, Mikami S, Pan CC, et al. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect. *Histol Histopathol* 2012;27:133–140.
92. Malinowska I, Kwiatkowski DJ, Weiss S, et al. Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. *Am J Surg Pathol* 2012;36:783–784.
93. Hodge JC, Pearce KE, Wang X, et al. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. *Mod Pathol* 2014;27:113–127.
94. Williams A, Bartle C, Sumathi VP, et al. Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features. *Virchows Arch* 2011;458:291–300.
95. Tsuji K, Ishikawa Y, Imamura T. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. *Hum Pathol* 2012;43:356–363.
96. Kobos R, Nagai M, Tsuda M, et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. *J Pathol* 2013;229:743–754.
97. Lazar AJ, Das P, Tuvlin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. *Clin Cancer Res* 2007;13:7314–7321.
98. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. *Histopathology* 2009;55:750–755.
99. Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). *BMC Cancer* 2009;9:22.
100. Vistica DT, Hollingshead M, Borgel SD, et al. Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy. *J Pediatr Hematol Oncol* 2009;31:561–570.
101. Kummer S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. *J Clin Oncol* 2013;31:2296–2302.
102. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. *J Clin Oncol* 2005;23:866–873.
103. O'Brien KP, Seroussi E, Dal Cin P, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. *Genes Chromosomes Cancer* 1998;23:187–193.
104. Pedetour F, Coindre JM, Sozzi G, et al. Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans? *Cancer Genet Cytogenet* 1994;76:1–9.
105. Simon MP, Pedetour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. *Nat Genet* 1997;15:95–98.
106. Patel KU, Szabo SS, Hernandez VS, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. *Hum Pathol* 2008;39:184–193.
107. Kiuru-Kuhlefelt S, El-Rifai W, Fanburg-Smith J, et al. Concomitant DNA copy number amplification at 17q and 22q in dermatofibrosarcoma protuberans. *Cytogenet Cell Genet* 2001;92:192–195.
108. Abbott JJ, Erickson-Johnson M, Wang X, et al. Gains of COL1A1-PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. *Mod Pathol* 2006;19:1512–1518.
109. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. *Cancer Res* 1999;59:3719–3723.
110. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. *Int J Cancer* 2002;100:623–626.
111. Sirvent N, Maire G, Pedetour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. *Genes Chromosomes Cancer* 2003;37:1–19.
112. Panagopoulos I, Mertens F, Isaksson M, et al. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. *Genes Chromosomes Cancer* 2002;35:340–352.
113. Sjogren H, Meis-Kindblom JM, Orndal C, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. *Am J Pathol* 2003;162:781–792.

114. Hisaoka M, Hashimoto H. Extraskeletal myxoid chondrosarcoma: updated clinicopathological and molecular genetic characteristics. *Pathol Int* 2005;55:453–463.
115. Sandberg AA. Genetics of chondrosarcoma and related tumors. *Curr Opin Oncol* 2004;16:342–354.
116. Ohkura N, Yaguchi H, Tsukada T, et al. The EWS/NOR1 fusion gene product gains a novel activity affecting pre-mRNA splicing. *J Biol Chem* 2002;277:535–543.
117. Bertolotti A, Lutz Y, Heard DJ, et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIIID and RNA polymerase II. *EMBO J* 1996;15:5022–5031.
118. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. *Oncogene* 2001;20:5747–5754.
119. Subramanian S, West RB, Marinelli RJ, et al. The gene expression profile of extraskeletal myxoid chondrosarcoma. *J Pathol* 2005;206:433–444.
120. Fletcher CDM, Bridge JA, Hogendoorn P, et al. eds. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon, France: IARC Press; 2013.
121. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. *Nat Genet* 2013;45:180–185.
122. Hajdu M, Singer S, Maki RG, et al. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. *J Pathol* 2010;221:300–307.
123. Li Y, Chang Q, Rubin BP, et al. Insulin receptor activation in solitary fibrous tumours. *J Pathol* 2007;211:550–554.
124. Zafar H, Takimoto CH, Weiss G. Doegje-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor. *Med Oncol* 2003;20:403–408.
125. Rossi G, Schirosi L, Giovanardi F, et al. Pleural malignant solitary fibrous tumor with sarcomatous overgrowth showing PDGFRbeta mutation. *Chest* 2006;130:581–583.
126. Sen-Gupta S, Van der Luijt RB, Bowles LV, et al. Somatic mutation of APC gene in desmoid tumour in familial adenomatous polyposis. *Lancet* 1993;342:552–553.
127. Okamoto M, Sato C, Kohno Y, et al. Molecular nature of chromosome 5q loss in colorectal tumors and desmoids from patients with familial adenomatous polyposis. *Hum Genet* 1990;85:595–599.
128. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol* 2008;173:1518–1527.
129. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). *Oncogene* 1999;18:6615–6620.
130. Kong Y, Poon R, Nadesan P, et al. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. *Cancer Res* 2004;64:5795–5803.
131. Ghanbari-Azamir R, Sato S, Wei Q, et al. Targeting stem cell behavior in desmoid tumors (aggressive fibromatosis) by inhibiting hedgehog signaling. *Neoplasia* (New York, NY) 2013;15:712–719.
132. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). *J Clin Oncol* 2006;24:1195–1203.
133. Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of Sorafenib against desmoid tumor/deep fibromatosis. *Clin Cancer Res* 2011;17:4082–4090.
134. Horvai AE, DeVries S, Roy R, et al. Similarity in genetic alterations between paired well-differentiated and dedifferentiated components of dedifferentiated liposarcoma. *Mod Pathol* 2009;22:1477–1488.
135. Rieker RJ, Weitz J, Lehner B, et al. Genomic profiling reveals subsets of dedifferentiated liposarcoma to follow separate molecular pathways. *Virchows Arch* 2010;456:277–285.
136. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. *Cancer Cell* 2007;11:361–374.
137. Snyder EL, Sandstrom DJ, Law K, et al. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. *J Pathol* 2009;218:292–300.
138. Wu YV, Okada T, DeCarolis P, et al. Restoration of C/EBPalpha in dedifferentiated liposarcoma induces G2/M cell cycle arrest and apoptosis. *Genes Chromosomes Cancer* 2012;51:313–327.
139. Gobble RM, Qin LX, Brill ER, et al. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis. *Cancer Res* 2011;71:2697–2705.
140. Crago AM, Socci ND, DeCarolis P, et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. *Clin Cancer Res* 2012;18:1334–1340.
141. Taylor BS, DeCarolis PL, Angeles CV, et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. *Cancer Discov* 2011;1:587–597.
142. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. *Cancer Res* 2007;67:6626–6636.
143. Ugras S, Brill E, Jacobsen A, et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. *Cancer Res* 2011;71:5659–5669.
144. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. *J Clin Oncol* 2013;31:2024–2028.
145. Taylor BS, Barretina J, Socci ND, et al. Functional copy-number alterations in cancer. *PLoS One* 2008;3:e3179.
146. Ambrosini G, Sambol EB, Carvajal D, et al. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. *Oncogene* 2007;26:3473–3481.
147. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. *J Clin Oncol* 2012;30:3633–3639.
148. Fletcher CD, Gustafson P, Rydholm A, et al. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. *J Clin Oncol* 2001;19:3045–3050.
149. Holloway K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? *Semin Diagn Pathol* 1995;12:210–220.
150. Bridge RS Jr, Bridge JA, Neff JR, et al. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. *J Clin Pathol* 2004;57:1172–1178.
151. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. *Chromosomes and Morphology. Genes Chromosomes Cancer* 1998;22:16–25.
152. Willems SM, Debiec-Rychter M, Szuhai K, et al. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. *Mod Pathol* 2006;19:407–416.
153. Weiss SW. Malignant fibrous histiocytoma. A reaffirmation. *Am J Surg Pathol* 1982;6:773–784.
154. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. *Cancer* 1978;41:2250–2266.
155. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. *Am J Surg Pathol* 1992;16:213–228.
156. Asperg F, Mertens F, Bauer HC, et al. Near-haploidy in two malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 1995;79:119–122.
157. Mandahl N, Heim S, Willen H, et al. Characteristic karyotypic anomalies identify subtypes of malignant fibrous histiocytoma. *Genes Chromosomes Cancer* 1989;1:9–14.
158. Schmidt H, Korber S, Hinze R, et al. Cytogenetic characterization of ten malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 1998;100:134–142.
159. Szymanska J, Tarikkanen M, Wiklund T, et al. A cytogenetic study of malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 1995;85:91–96.
160. Walter TA, Weh HJ, Schlag PM, et al. Cytogenetic studies in malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 1997;94:131–134.
161. Kresse SH, Ohnstad HO, Bjerkehagen B, et al. DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation. *PLoS One* 2010;5:e15378.
162. Chibon F, Mairal A, Freneaux P, et al. The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma. *Cancer Res* 2000;60:6339–6345.
163. Derre J, Lagace R, Nicolas A, et al. Leiomyosarcomas and most malignant fibrous histiocytomas share very similar comparative genomic hybridization imbalances: an analysis of a series of 27 leiomyosarcomas. *Lab Invest* 2001;81:211–215.
164. Parente F, Grosgeorge J, Coindre JM, et al. Comparative genomic hybridization reveals novel chromosome deletions in 90 primary soft tissue tumors. *Cancer Genet Cytogenet* 1999;115:89–95.
165. Chibon F, Mariani O, Derre J, et al. ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. *Genes Chromosomes Cancer* 2004;40:32–37.
166. Chibon F, Mariani O, Derre J, et al. A subgroup of malignant fibrous histiocytomas is associated with genetic changes similar to those of well-differentiated liposarcomas. *Cancer Genet Cytogenet* 2002;139:24–29.
167. Chibon F, Mariani O, Mairal A, et al. The use of clustering software for the classification of comparative genomic hybridization data: an analysis of 109 malignant fibrous histiocytomas. *Cancer Genet Cytogenet* 2003;141:75–78.
168. Simons A, Schepens M, Jeuken J, et al. Frequent loss of 9p21 (p16(INK4A)) and other genomic imbalances in human malignant fibrous histiocytoma. *Cancer Genet Cytogenet* 2000;118:89–98.
169. Reid AH, Tsai MM, Venzon DJ, et al. MDM2 amplification, P53 mutation, and accumulation of the P53 gene product in malignant fibrous histiocytoma. *Diagn Mol Pathol* 1996;5:65–73.
170. Taubert H, Wurl P, Meyer A, et al. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas. *Cancer* 1995;76:1187–1196.
171. Yoo J, Lee HK, Kang CS, et al. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. *Arch Pathol Lab Med* 1997;121:395–399.
172. Wang CY, Wei Q, Han I, et al. Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. *Cancer Res* 2012;72:1013–1022.
173. Mandahl N, Fletcher CD, Dal Cin P, et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group. *Cancer Genet Cytogenet* 2000;116:66–73.

174. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. *Cancer Genet Cytogenet* 2005;161:1–19.
175. Yang J, Du X, Chen K, et al. Genetic aberrations in soft tissue leiomyosarcoma. *Cancer Lett* 2009;275:1–8.
176. Wang R, Titley JC, Lu YJ, et al. Loss of 13q14-q21 and gain of 5p14-pter in the progression of leiomyosarcoma. *Mod Pathol* 2003;16:778–785.
177. Hu J, Rao UN, Jasani S, et al. Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study. *Cancer Genet Cytogenet* 2005;161:20–27.
178. Perot G, Derre J, Coindre JM, et al. Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas. *Cancer Res* 2009;69:2269–2278.
179. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. *Nat Med* 2007;13:748–753.
180. Guijarro MV, Dahiya S, Danielson LS, et al. Dual Pten/Trp53 suppression promotes sarcoma progression by activating Notch signaling. *Am J Pathol* 2013;182:2015–2027.
181. Mita MM, Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. *Curr Oncol Rep* 2007;9:316–322.
182. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). *Cancer* 2011;117:3468–3475.
183. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. *J Natl Cancer Inst* 2007;99:24–31.
184. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. *J Med Genet* 2002;39:311–314.
185. Ducatman BS, Scheithauer BW, Piegras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. *Cancer* 1986;57:2006–2021.
186. Mantripragada KK, Spurlock G, Kluwe L, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. *Clin Cancer Res* 2008;14:1015–1024.
187. Perry A, Roth KA, Banerjee R, et al. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. *Am J Pathol* 2001;159:57–61.
188. Lothe RA, Slettan A, Saeter G, et al. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. *J Neuropathol Exp Neurol* 1995;54:65–73.
189. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. *Cell* 2001;104:593–604.
190. Carroll SL, Ratner N. How does the Schwann cell lineage form tumors in NF1? *Glia* 2008;56:1590–1605.
191. Mantripragada KK, de Stahl TD, Patridge C, et al. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array. *Genes Chromosomes Cancer* 2009;48:897–907.
192. Upadhyaya M, Kluwe L, Spurlock G, et al. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). *Hum Mutat* 2008;29:74–82.
193. Fletcher CD, Dal Cin P, de Wever I, et al. Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. *Am J Pathol* 1999;154:1841–1847.
194. Mertens F, Dal Cin P, De Wever I, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. *J Pathol* 2000;190:31–38.
195. Kresse SH, Skarn M, Ohnstad HO, et al. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. *Mol Cancer* 2008;7:48.
196. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *J Clin Oncol* 2003;21:4586–4591.
197. Storlazzi CT, Brekke HR, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. *J Pathol* 2006;209:492–500.
198. Agesen TH, Florenes VA, Molenaar WM, et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. *J Neuropathol Exp Neurol* 2005;64:74–81.
199. Birindelli S, Perrone F, Oggionni M, et al. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. *Lab Invest* 2001;81:833–844.
200. Keizman D, Issakov J, Meller I, et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. *J Neurooncol* 2009;94:383–388.
201. Ling BC, Wu J, Miller SJ, et al. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. *Cancer Cell* 2005;7:65–75.
202. Rahrman EP, Watson AL, Keng VW, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. *Nat Genet* 2013;45:756–766.
203. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. *Proc Natl Acad Sci U S A* 2005;102:8573–8578.
204. Mo W, Chen J, Patel A, et al. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. *Cell* 2013;152:1077–1090.
205. Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. *Mol Cancer Ther* 2008;7:890–896.
206. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. *J Clin Oncol* 2009;27:3133–3140.
207. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. *Cancer Res* 2009;69:7175–7179.
208. Manner J, Radwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. *Am J Pathol* 2010;176:34–39.
209. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. *Genes Chromosomes Cancer* 2011;50:25–33.
210. Italiano A, Thomas R, Breen M, et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. *Genes Chromosomes Cancer* 2012;51:569–578.
211. Schwartz HS, Zimmerman NB, Simon MA, et al. The malignant potential of enchondromatosis. *J Bone Joint Surg Am* 1987;69:269–274.
212. Tiet TD, Hopyan S, Nadesan P, et al. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. *Am J Pathol* 2006;168:321–330.
213. Hopyan S, Gokgoz N, Poon R, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. *Nat Genet* 2002;30:306–310.
214. Rozeman LB, Sangiorgi L, Briaire-de Bruijn IH, et al. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHrP mutation p.R150C. *Hum Mutat* 2004;24:466–473.
215. Couvineau A, Wouters V, Bertrand G, et al. PTHrP mutations associated with Ollier disease result in receptor loss of function. *Hum Mol Genet* 2008;17:2766–2775.
216. Jennes I, Pedrini E, Zuntini M, et al. Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). *Hum Mutat* 2009;30:1620–1627.
217. Bovee JV, Cleton-Jansen AM, Wuyts W, et al. EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. *Am J Hum Genet* 1999;65:689–698.
218. Hameetman L, Szuhai K, Yavas A, et al. The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions. *J Natl Cancer Inst* 2007;99:396–406.
219. Jones KB, Piombo V, Seaby C, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. *Proc Natl Acad Sci U S A* 2010;107:2054–2059.
220. Bovee JV. EXT1a hit for mouse osteochondroma. *Proc Natl Acad Sci U S A* 2010;107:1813–1814.
221. McCormick C, Leduc Y, Martindale D, et al. The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. *Nat Genet* 1998;19:158–161.
222. Benoist-Lasselin C, de Margerie E, Gibbs L, et al. Defective chondrocyte proliferation and differentiation in osteochondromas of MHE patients. *Bone* 2006;39:17–26.
223. St-Jacques B, Hammerschmidt M, McMahon AP. Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev* 1999;13:2072–2086.
224. Amary MF, Bacs K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J Pathol* 2011;224:334–343.
225. Kerr DA, Lopez HU, Deshpande V, et al. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations. *Am J Surg Pathol* 2013;37:787–795.
226. Damato S, Alorjani M, Bonar F, et al. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas. *Histopathology* 2012;60:363–365.
227. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. *Science* 2009;324:261–265.
228. Lin C, McGough R, Aswad B, et al. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. *J Orthop Res* 2004;22:1175–1181.
229. Kubo T, Sugita T, Shimose S, et al. Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. *J Bone Joint Surg Br* 2008;90:364–370.
230. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* 2009;462:739–744.
231. Ward PS, Cross JR, Lu C, et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. *Oncogene* 2012;31:2491–2498.

232. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. *Nature* 2012;483:479–483.
233. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010;18:553–567.
234. Guilhamon P, Eskandarpour M, Halai D, et al. Meta-analysis of IDH1-mutant cancers identifies EBF1 as an interaction partner for TET2. *Nat Commun* 2013;4:2166.
235. Lu C, Venneti S, Akalin A, et al. Induction of sarcomas by mutant IDH2. *Genes Dev* 2013;27:1986–1998.
236. Popovici-Muller J, Saunders JO, Salituro FC, et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. *ACS Med Chem Lett* 2012;3:850–855.
237. Tarpey PS, Behjati S, Cooke SL, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. *Nat Genet* 2013;45:923–926.
238. Schrage YM, Hameetman L, Zuhai K, et al. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. *Am J Pathol* 2009;174:979–988.
239. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med* 2009;361:1173–1178.
240. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* 2009;361:1164–1172.
241. Ruch JM, Kim EJ. Hedgehog signaling pathway and cancer therapeutics: progress to date. *Drugs* 2013;73:613–623.
242. Hameetman L, Rozeman LB, Lombaerts M, et al. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling. *J Pathol* 2006;209:501–511.
243. Ho L, Stojanovski A, Whetstone H, et al. Gli2 and p53 cooperate to regulate IGF1R-mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. *Cancer Cell* 2009;16:126–136.
244. Schrage YM, Briaire-de Bruijn IH, de Miranda NF, et al. Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. *Cancer Res* 2009;69:6216–6222.
245. Raymond AK, Ayala AG, Knuutila S. Conventional osteosarcoma. In: Fletcher CD, Unni KK, Mertens F, eds. *Pathology and Genetics of Tumors of Soft Tissue and Bone*. Lyon, France: IARC Press; 2002: 264–270.
246. Skubitz KM, D'Adamo DR. Sarcoma. *Mayo Clin Proc* 2007;82:1409–1432.
247. Dick DC, Morley WN, Watson JT. Rothmund-Thomson syndrome and osteogenic sarcoma. *Clin Exp Dermatol* 1982;7:119–123.
248. Belchis DA, Meece CA, Benko FA, et al. Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas. *Diagn Mol Pathol* 1996;5:214–219.
249. Feugeas O, Guriec N, Babin-Boilletot A, et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. *J Clin Oncol* 1996;14:467–472.
250. Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. *Cancer Res* 1994;54:3042–3048.
251. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. *Int J Cancer* 1999;80:199–204.
252. Nielsen GP, Burns KL, Rosenberg AE, et al. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. *Am J Pathol* 1998;153:159–163.
253. Gokgoz N, Wunder JS, Mousses S, et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. *Cancer* 2001;92:2181–2189.
254. Overholzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. *Proc Natl Acad Sci U S A* 2003;100:11547–11552.
255. Lonardo F, Ueda T, Huvos AG, et al. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. *Cancer* 1997;79:1541–1547.
256. Chen W, Cooper TK, Zahnow CA, et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. *Cancer Cell* 2004;6:387–398.
257. Man TK, Lu XY, Jaewon K, et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. *BMC Cancer* 2004;4:45.
258. Squire JA, Pei J, Marrano P, et al. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. *Genes Chromosomes Cancer* 2003;38:215–225.
259. Atiye J, Wolf M, Kaur S, et al. Gene amplifications in osteosarcoma-CGH microarray analysis. *Genes Chromosomes Cancer* 2005;42:158–163.
260. Zielenska M, Marrano P, Thorne P, et al. High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. *Cytogenet Genome Res* 2004;107:77–82.
261. Tarkkanen M, Karhu R, Kallioniemi A, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. *Cancer Res* 1995;55:1334–1338.
262. Ozaki T, Schaefer KL, Wai D, et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas. *Int J Cancer* 2002;102:355–365.
263. Stock C, Kager L, Fink FM, et al. Chromosomal regions involved in the pathogenesis of osteosarcomas. *Genes Chromosomes Cancer* 2000;28:329–336.
264. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. *J Natl Cancer Inst* 2003;95:669–674.
265. Tiet TD, Alman BA. Developmental pathways in musculoskeletal neoplasia: involvement of the Indian Hedgehog-parathyroid hormone-related protein pathway. *Pediatr Res* 2003;53:539–543.
266. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013;63:11–30.
267. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet* 2009;10:57–63.
268. Wold B, Myers RM. Sequence census methods for functional genomics. *Nat Methods* 2008;5:19–21.
269. Pepke S, Wold B, Mortazavi A. Computation for ChIP-seq and RNA-seq studies. *Nat Methods* 2009;6:S22–S32.
270. Mortazavi A, Williams BA, McCue K, et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods* 2008;5:621–628.
271. Deluca LJ, Hamrick D, Cosenza L, et al. Protein crystallization: virtual screening and optimization. *Prog Biophys Mol Biol* 2005;88:285–309.
272. Sharp SY, Prodromou C, Boxall K, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinolic pyrazole/isoxazole amide analogues. *Mol Cancer Ther* 2007;6:1198–1211.
273. Oltsersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 2005;435:677–681.
274. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. *Nat Rev Cancer* 2008;8:473–480.
275. Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. *Nat Rev Drug Discov* 2005;4:649–663.
276. Sugita S, Seki K, Yokozawa K, et al. Analysis of CHOP rearrangement in pleomorphic liposarcomas using fluorescence in situ hybridization. *Cancer Sci* 2009;100:82–87.
277. Terry J, Barry TS, Horsman DE, et al. Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakpoint-style probe. *Diagn Mol Pathol* 2005;14:77–82.
278. Meier VS, Kuhne T, Jundt G, et al. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. *Diagn Mol Pathol* 1998;7:29–35.
279. Argani P, Lal P, Hutchinson B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. *Am J Surg Pathol* 2003;27:750–761.
280. Barr FC, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. *J Mol Diagn* 2006;8:202–208.
281. Mandahl N, Heim S, Willen H, et al. Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans. *Cancer Genet Cytogenet* 1990;49:273–275.
282. Hisaoka M, Ishida T, Kuo TT, et al. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. *Am J Surg Pathol* 2008;32:452–460.
283. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. *Science* 2003;299:708–710.
284. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. *Science* 1998;279:577–580.
285. Tanas MR, Goldblum JR. Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. *Adv Anat Pathol* 2009;16:383–391.